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Abstract
Background: As in many other European countries, a nationwide screening program for colorectal cancer (CRC)
has recently been introduced in the Netherlands. As a side effect, such a screening program will inherently yield an
increase in the demand for surveillance after removal of polyps/adenomas or CRC. Although these patients are at
increased risk of metachronous colorectal neoplasia, solid evidence on CRC-related mortality reduction as a result of
colonoscopy-based surveillance programs is lacking. Furthermore, colonoscopy-based surveillance leads to high
patient burden, high logistic demands and high costs. Therefore, new surveillance strategies are needed. The aim of
the present study, named Molecular stool testing for Colorectal CAncer Surveillance (MOCCAS), is to determine the
performance characteristics of two established non-invasive tests, i.e., the multitarget stool DNA test Cologuard®
and the faecal immunochemical test (FIT) in the detection of CRC and advanced adenomas as an alternative for
colonoscopy surveillance.
Methods: In this observational cross-sectional cohort study, subjects aged 50 to 75 years will be approached to
collect (whole-) stool samples for molecular testing and a FIT prior to their scheduled surveillance colonoscopy. The
results of the tests will allow calculation of test sensitivities and specificities in the context of surveillance. This will
provide the required input for the Dutch ASCCA model (Adenoma and Serrated pathway to Colorectal CAncer) to
simulate surveillance strategies differing in frequency and duration. The model will allow predictions of lifetime
health effects and costs. Multiple centres in the Netherlands will participate in the study that aims to include 4,000
individuals.
Discussion: The outcome of this study will inform on the (cost-) effectiveness of stool based molecular testing as
an alternative for colonoscopy in the rapidly expanding surveillance population.
Trial registration: ClinicalTrials.gov (https://clinicaltrials.gov/): NCT02715141. Retrospectively registered
17 February 2016.
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Background
Colorectal cancer (CRC) is a major health concern world-
wide, ranking third in males and second in females, with
over 1.2 million new cancer cases and an estimated
608,700 deaths in 2008 [1]. Survival of colorectal cancer is
inversely related to the stage at diagnosis. Five-year
survival rates range from more than 90% for stage I to less
than 10% for stage IV CRC [2]. Therefore, detection and
removal of the tumour in an early, or preferably, a prema-
lignant stage is vital [3]. Since CRC often only becomes
symptomatic when progressed to an advanced state,
secondary prevention through screening is an important
instrument for reducing death from CRC [4].
CRC as a disease lends itself well for screening as it
has a high prevalence and a well-defined precursor
lesion (i.e., adenoma) with a long dwell-time, providing
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an excellent window of opportunity for detection and
resection of a lesion before becoming symptomatic.
Indeed, incidence and mortality rates of CRC have de-
clined in countries where screening has been introduced
[5–7]. Recently a nationwide screening programme was
also implemented in the Netherlands, using a faecal
immunochemical test (FIT). Men and women aged 55 to
75 years are invited every 2 years, which amounts to a
total number of 2.2 million individuals per year in the
Netherlands being invited to participate in the program.
Of the estimated 7% FIT-positive screenees, approxi-
mately half will have advanced adenomas or carcinomas
at colonoscopy, equal to over 45.000 individuals annually
[8]. As these patients carry an increased risk to develop
metachronous advanced lesions in the future [9–12] it
is standard practice to enrol these individuals in a
colonoscopy-based surveillance program [13–15].
There are several downsides, though, to the current
approach for managing the cancer risk in the surveillance
population. Firstly, evidence of the impact of current sur-
veillance strategies on the ultimate endpoint CRC-related
mortality is very limited. The effect of surveillance has
primarily been evaluated for intermediate endpoints, i.e.,
the yield of (advanced) adenomas upon surveillance col-
onoscopy [12, 16]. However, adenomas are very common
with a prevalence of 18-35% reported in screening series
[17, 18], whilst only up to 5% of these adenomas will
eventually progress to malignancy [19]. This suggests that
focussing on adenoma yield as a primary endpoint repre-
sents actual overdiagnosis. Moreover, the technical
advancements in colonoscopy-equipment and the recent
emphasis on quality assurance have resulted in increas-
ingly more and often smaller adenomas being detected.
These small lesions are more likely to remain stable over
time [20, 21]. As a result, the surveillance population will
expand even further, putting the colonoscopy capacity and
health care budgets under pressure [22, 23]. Finally, it will
expose post-polypectomy patients to a burdensome and
risky procedure that has not proven to be effective for this
population.
For these reasons there is a demand for a surveillance
tool that is easy to apply, well-tolerated and accurate in
identifying high risk adenomas, as to reserve colonos-
copy only for those individuals that are most likely to
benefit.
Today, despite its limitations, colonoscopy is still the
only test used for surveillance of patients after removal
of polyps and CRC. The FIT, which detects small
amounts of human haemoglobin in the faeces, has been
proposed as a method for surveillance [24]. While sim-
ple and increasing the likelihood of neoplasia being
present when positive, its sensitivity is relatively low due
to the fact that not all CRCs, and especially not all
advanced adenomas bleed [25, 26]. Yet, it was shown
that the diagnosis of CRC and advanced adenomas was
made 25 and 24 months (median) earlier, respectively,
when offering a yearly FIT in the interval between
colonoscopies and shortening the interval in case of a
positive test. This indicates that FIT could be used to de-
tect missed or rapidly developing lesions in surveillance
programs [24].
In contrast to tests detecting blood, tests based on
molecular markers derived from the neoplastic cells in
the colon have the potential to be more accurate. CRCs
are known to acquire discriminating epigenetic and
genetic changes as they develop and progress, which
form the basis of stool based DNA testing. Recently, a
multitarget stool DNA test (Cologuard®, Exact Sciences,
Madison, WI, USA) combining a molecular assay for
hypermethylated promoter CpG islands (NDRG4 and
BMP3) and mutant KRAS with an immunoassay for
human haemoglobine has been reported on [27]. Sensi-
tivities for the detection of CRC were 92.3% with Colo-
guard® and 73.8% with FIT (p =0.015). Also, Cologuard®
detected significantly more advanced adenomas than the
FIT (69.2% versus 46.2%, p = 0.004) and significantly
more sessile serrated polyps measuring 1 cm or more
(42.4% versus 5.1%). Specificities of Cologuard® and FIT
were 86.6 and 94.9%, respectively. The results of this
study have led to FDA approval of Cologuard® in 2014.
We hypothesise that Cologuard®- or FIT-based surveil-
lance is a cost-effective first-line surveillance strategy to
select individuals that need colonoscopy for diagnosis
confirmation and therapeutic removal.
Objective
Primary objective
The primary goal of this study named Molecular stool
testing for Colorectal CAncer Surveillance (MOCCAS),
is to evaluate the performance of the molecular stool
test Cologuard® in post-polypectomy, CRC and FCC
surveillance. To this end, we will determine the perform-
ance characteristics of Cologuard® in the detection of
CRC and advanced adenomas in a surveillance setting.
The performance of Cologuard® will be compared to two
commercially available FITs (OC-sensor (Eiken Chemical
Co., Tokyo, Japan) and FOB Gold (Sentinel, Milan,
Italy)) and the gold standard colonoscopy. The test
performance data will be used as input in the ASCCA
(Adenoma and Serrated pathway to Colorectal CAncer)
model that was developed using Dutch data [28]. The
model will allow predictions of lifetime health effects
and costs for a number of surveillance strategies differ-
ing in frequency and duration (Fig. 1).
Secondary objectives
As a secondary objective, we aim to analyse whether the
diagnostic markers included in Cologuard® are present
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in the tissue samples of lesions identified and removed
during the surveillance colonoscopy procedure. These
data will then be correlated to the Cologuard® results. In
addition, these same tissue samples will be analysed for
the presence of particular genomic alterations known to
be indicative of progression to cancer [29] and the
performance of Cologuard® will be determined for
detecting such high risk precursor lesions. This will
allow refined analysis of the diagnostic performance
of these assays. Through modelling, the impact of
using a molecular-based definition of high risk aden-
oma on predicted health effect and burden will be
assessed for alternative surveillance strategies. More-
over, we will incorporate previously identified risk
factors for the development of advanced neoplasia in
the model [30]. To this end participants will be asked
to complete a validated online questionnaire including
these risk factors [31].
Methods
Study design
This is a multi-centre, cross-sectional observational
cohort study in the Netherlands that aims to include
4,000 patients. The study has been approved by the
Medical Ethical Committee of the Academic Medical
Center (AMC), Amsterdam and has been registered in
ClinicalTrials.gov (NCT02715141).
Study population
All individuals that have an indication for a surveillance
colonoscopy according to the previous (2001) [15] or
current (2013) [15] Dutch guidelines are eligible for this
study. Those guidelines include subjects with a history of
polypectomy or CRC, as well as subjects under surveil-
lance for familial colorectal cancer (FCC). In order to
complete the risk questionnaire and give informed con-
sent, subjects must have sufficient understanding of the
Dutch language. Subjects with inflammatory bowel disease
(IBD) or genetic cancer syndromes such as Lynch
syndrome, familial adenomatous polyposis (FAP), attenu-
ated FAP (AFAP), MUTYH associated polyposis (MAP),
serrated polyposis syndrome (SPS) and other polyposis
syndromes are excluded from participation. Also, a colon-
oscopy in the previous 6 months, having undergone a
proctocolectomy or a life expectancy of less than three
years are exclusion criteria.
Fig. 1 Overview of the MOCCAS study. * FIT = faecal immunochemical test, consisting of the OC-sensor® (Eiken Chemical Co., Tokyo, Japan) and
FOB Gold® (Sentinel, Milan, Italy). ASCCA = Adenoma and Serrated pathway to Colorectal Cancer. Individuals with an indication for surveillance
colonoscopy are selected and invited to participate. After oral consent the home stool collection kit is sent to the individuals home address. The
test results of Cologuard® (Exact Sciences, Madison, WI, USA) and FIT will be compared to the findings described in the colonoscopy and
pathology report in order to yield the test performances. This will then feed the ASCCA model for the simulation of different surveillance
strategies. The tissue of lesions removed during the surveillance colonoscopy will be used for molecular analysis of progression biomarkers to define
high risk adenomas. This alternative, molecular-based intermediate endpoint will impact the test performances and thus the ASCCA modelling. By
adding identified risk factors to the obtained test performance data, new sensitivity data will be acquired and used to repeat the model simulations
of surveillance strategies
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Study algorithm
Subject recruitment and sample collection
Subjects will be invited to participate one to two weeks
prior to their routine surveillance colonoscopy by a
member of the research team. When oral consent is
given, a package containing the study information and
-instructions, informed consent form, FITs and stool
collection kit will be sent to their home address. Simul-
taneously, an email containing the link to the online
questionnaire will be sent, or a hardcopy version of the
questionnaire will be added to the package in case email
is not available. This validated questionnaire evaluates
the risk factors: age, body mass index (BMI), family
history for CRC (first degree relatives), regular aspirin or
non-steroid anti-inflammatory drug (NSAID) use, current
smoking, history of smoking, alcohol intake, total calcium
intake, physical activity and postmenopausal hormone re-
placement therapy [31]. Regular NSAID intake is defined
as the use of NSAIDs three or more times a week during
the last month. Calcium intake is estimated by questions
about food and supplement intake [31].
For stool collection as part of Cologuard®, a dedicated
kit is used as provided by Exact Sciences. This kit com-
prises materials to collect at home stool from one full
bowel movement (whole stool sample), in an easy and
hygienic way. Subjects are instructed to collect the stool
sample, perform FIT-sampling by swiping the test on the
faecal surface, and afterwards add stabilisation buffer to
the remaining stool sample for DNA preservation. The
sealed samples may be stored at room temperature until
the colonoscopy appointment. The allowed time frame
between collection of the sample and processing in the
laboratory is restricted to 72 h.
On arrival at the endoscopy department subjects will
hand in the signed informed consent form and the
sealed package containing the whole stool- and FIT-
samples. Samples from individuals of whom written in-
formed consent is lacking will be excluded from further
processing or analysis. The sealed package will be stored
at the endoscopy department until transfer to the
laboratory by a courier service.
Laboratory procedures
On arrival in the laboratory the FITs and the whole stool
sample will be handled separately. The FITs used are
automated tests (OC-sensor®, Eiken Chemical Co.,
Tokyo, Japan and FOB Gold®, Sentinel, Milan, Italy) with
a quantitative outcome. The FITs will be analysed on the
OC –sensor DIANA (Eiken Chemical Co.) and SENTi-
FIT 270 (Sentinel) according to the manufacturer’s in-
structions by an experienced technician, who is unaware
of the colonoscopy outcomes. The stool sample will be
homogenised, aliquoted and stored at −80 °C. The
homogenised samples will be shipped in batches under
strict conditions to Exact Science Corporation for
analysis. As Cologuard® is composed of a molecular
assay plus an immunochemical test for haemoglobin
detection, an algorithm derived from these two assays
will determine the test result. Researchers performing
the analyses will be blinded for the colonoscopy results.
The diagnostic results of the FITs and Cologuard® will
be compared to the yield of colonoscopy. Colonoscopy
is the gold standard, and neither participants nor doctors
will be informed about the test results.
Second, tissue samples of lesions removed during the
surveillance colonoscopy procedure will be collected
from the pathology archives and subjected to further
molecular characterisation. Expression of the diagnostic
Cologuard® markers will be tested through methylation-
specific PCR and mutation analysis in order to deter-
mine which polyps are likely to have contributed to the
test result. In a separate analysis, DNA copy number
changes that are associated with adenoma to carcinoma
progression will be assessed for the identification of high
risk adenomas [29]. These changes include losses in
8p21-pter, 15q11-q21, 17p12-13, and 18q12-21, and
gains in 8q23-qter, 13q14-31, and 20q13. The presence
of two or more of the seven aforementioned chromo-
somal changes defines a high risk adenoma.
Clinical procedures
Colonoscopies (with conscious sedation) will be per-
formed or supervised by experienced gastroenterologists.
A complete colonoscopy will be defined as intubation of
the caecum with identification of the ileocaecal valve or
appendiceal orifice. Quality parameters for colonoscopy
will be reported [32, 33]. Patients with an incomplete
colonoscopy and/or insufficient bowel preparation will
be rescheduled for colonoscopy. Patients that undergo
the re-colonoscopy at more than 26 weeks (6 months)
after the initial surveillance colonoscopy, and thus
collection of the whole stool sample, will be excluded for
analyses. Only in case of detection of CRC, an incomplete
colonoscopy is no reason for exclusion.
Lesions that are resected during surveillance colonos-
copy, will be evaluated by pathologists at the participating
centres. Adenomas ≥ 10 mm, with high-grade dysplasia
and/or villous characteristics (i.e., tubulovillous or villous
adenoma) will be classified as advanced adenomas
[13–15]. CRC and/or advanced adenomas are considered
advanced neoplasia. CRC will be staged according to the
AJCC cancer and TNM staging manual [34].
Formalin-fixed paraffin-embedded (FFPE) tissue sam-
ples from all the lesions removed during colonoscopy
will be stored in the respective pathology departments of
the participating centres. These FFPE blocks will be
retrieved for molecular analysis through the Dutch
national pathology registry (PALGA) [35] and the Dutch
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National Tissuebank Portal (DNTP) [36], in the context
of the Biobanking and BioMolecular resources Research
Infrastructure the Netherlands (BBMRI-NL).
Data collection
Clinical data will be collected in a database, which is
validated to global regulatory standards. Variables that
will be assessed include subject age, sex, indication and
date of current surveillance colonoscopy, recommended
surveillance interval and findings of the previous colon-
oscopies. For our main study endpoint, i.e., the accuracy
of Cologuard® and FIT in detecting advanced neoplasia,
endoscopic- and pathologic characteristics of the lesions
found during the subsequent surveillance colonoscopy
will be collected.
A dedicated system for registering laboratory- and
pathology processes will be used to gather information
on the test characteristics and results of Cologuard® and
FITs.
Data analysis
Accuracy of Cologuard® and FIT
This study will yield estimates for relative sensitivity and
specificity of Cologuard® and FITs versus colonoscopy.
The analyses will be based on data from all participants
who had valid results on Cologuard® and/or FIT and
colonoscopy. In case of missing values on outcome
variables, the patient will be excluded. Exact binomial
confidence intervals will be calculated around relative
sensitivity, relative specificity, positive and negative pre-
dictive values.
Estimation of lesion specific positivity rates required for
model-based analyses
For the cost-effectiveness analyses comparing multiple
surveillance strategies, the ASCCA model (Adenoma
and Serrated pathway to Colorectal Cancer) will be used.
The ASCCA model describes the development of colo-
rectal cancer from adenomatous and serrated precursor
lesions. As input, the ASCCA model requires test posi-
tivity rates per lesion in each of the model categories of
no/small/medium/large adenomas and serrated lesions.
These cannot be directly taken from the cross-sectional
diagnostic study; the study yields estimates for relative
sensitivity and specificity of Cologuard® and FITs versus
colonoscopy, because colonoscopy is treated as the gold
standard. Therefore, we apply a process called calibra-
tion. In essence, test-specific positivity rates per lesion
are drawn randomly from a wide range of probable
values. Subsequently, the model is used to simulate the
present cross-sectional surveillance study using these
randomly drawn positivity rates. Predictions for the
number of positive test results within individuals with
small/medium/large adenomas and serrated lesions on
colonoscopy are compared to the observed data for
Cologuard® and FITs. Sets of positivity rates that repro-
duce the observed data are kept, whereas estimates that
produce predictions that diverge from the data are dis-
carded. For this calibration process, we will run ~10 K+
simulations each involving ~100 K+ individuals (the
actual number will depend on stopping criteria for
achieving less than a pre-specified level of statistical
uncertainty around the predictions). Statistical methods
to assess goodness-of-fit will be used to identify the
best-fitting sets of positivity rates.
Modelling alternative surveillance strategies
The surveillance schedule from the Dutch guidelines
‘Colonoscopy Surveillance’ (2013) [15] will be imple-
mented in the ASCCA model. Subsequently, alternative
surveillance strategies will be implemented using the
estimates for lesion-specific positivity rates as described
in the paragraph above. Different frequencies of molecu-
lar testing with Cologuard® and FIT (every 1, 1.5 or
2 years) and rules for referral back to the screening
population (after 3, 4, or 5 consecutive negative tests)
will be evaluated.
Each model evaluation will involve simulation of
1,000,000 individuals, which represents a ‘virtual’ sample
of the Dutch surveillance population. Predicted out-
comes will include cancer incidence and mortality, re-
source utilisation (including number of surveillance tests
and demand for colonoscopies) and cost-effectiveness.
The evaluation will be accompanied by extensive sensi-
tivity analyses in which, among others, the impact of
changes in adenoma and serrated lesion incidence in the
surveillance population, test positivity rates in each of
the size categories and costs of molecular testing will be
evaluated.
Modelling the impact of molecularly defined high risk
adenomas
In the current version of the model, only advanced aden-
omas have the possibility to progress to CRC. Advanced
adenomas in the model are defined on the basis size and
histology. To evaluate the impact of an alternative,
molecular-based intermediate endpoint, we will extend
the ASCCA model such that it includes the most rele-
vant progression biomarkers [29]. That is, on the basis
of these progression biomarkers, the category ‘advanced
adenoma’ will be replaced by ‘molecularly high risk
adenoma’.
Transition probabilities from the different adenoma
health states to a high risk adenoma will be derived by
the automatic calibration procedure as described above,
such that the molecular version of the ASCCA model
also correctly reproduces Dutch age- and sex-specific
adenoma prevalence and serrated polyp prevalence, the
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observed proportion of molecularly high risk adenomas
within the subgroups of small/medium/large adenomas,
and Dutch CRC incidence and mortality. The result will
be the first CRC surveillance model that includes the
molecular biology of CRC development.
The model will then be used to repeat the described
simulation analyses of alternative surveillance strategies.
The hypothesis is that the predictions for health benefits
and cost-effectiveness of molecular stool test-based
surveillance are underestimated, because the current
classification ignores the ability of Cologuard® to detect
specifically those adenomas at high risk of progression.
Modelling the impact of a risk-based questionnaire
We will build a multivariable logistic regression model
by adding all risk factors from the questionnaire and the
obtained accuracy data from Cologuard® and FITs, using
advanced neoplasia as the dependent variable. Missing
data in the questionnaires will be handled by multiple
imputations. The newly obtained sensitivity data will be
used to repeat the model simulations of surveillance
strategies.
Sample size calculation
Based on previous reports [27, 37], we assume for the
power analysis that Cologuard® has a sensitivity of 50%
for advanced adenomas in individuals under surveil-
lance. To obtain an accuracy of 5% around the sensitivity
estimate (SE 2.5%, 95% confidence interval of width
10%), a total of 400 individuals with advanced neoplasia
are needed. In a recent Dutch surveillance study an
advanced adenoma was found in one per ten individuals
[22]. Based on this ratio, we will include 4,000 individ-
uals in the current study. This will allow a highly accur-
ate estimate of the specificity of Cologuard® and FIT in
this population (estimated width of 95% confidence
interval = 2%).
Discussion
In this cross-sectional observational cohort MOCCAS
study, the performance of a multitarget stool DNA test
(Cologuard®) and FITs will be assessed as an alternative
for surveillance colonoscopy. To this end, the results of
the stool based molecular tests and FITs will be com-
pared to the findings of the (routine) colonoscopy in a
surveillance population. These data will then be used as
input for model-based analyses. By simulating different
surveillance strategies varying in testing frequency and
rules for referral to the screening population, the model
will predict outcomes such as cancer incidence and
mortality, resource utilisation and cost-effectiveness.
Multiple modalities are available in the prevention of
CRC. Colonoscopy is a one-staged method in which
lesions are detected and removed simultaneously. Other
methods, such as CT-colonography, faecal immuno-
chemical tests and multitarget stool DNA tests, are two-
staged and are used as triage for colonoscopy. The two-
staged methods are associated with lower sensitivities,
but are generally advantageous in terms of participation
rates, risks and costs [27, 28, 38]. When choosing an
optimal strategy it should be emphasised that the weight
of these factors is different for surveillance compared to
screening. Where screening targets the “healthy” popula-
tion, surveillance is aimed at a narrow high risk group
with a higher positivity rate for colonoscopy. Sensitivity
of the method is therefore most important. The accuracy
of molecular tests might approach colonoscopy in the
detection of (high risk) colorectal polyps and –carcin-
omas when the test is performed more frequently than
colonoscopy. Participation in these high risk groups is
generally high, as a result of a patient’s awareness of his/
her risk.
The optimal model-predicted surveillance strategy, as
identified in the current study, will be evaluated in
clinical practice through a randomised study. Besides
investigating a potential alternative to surveillance col-
onoscopy, this study will generate new insights in the
molecular profiles of precancerous lesions by relating
the expression of both diagnostic biomarkers and
progression biomarkers to the results of Cologuard®.
Moreover, because whole stool samples, as well as FIT
samples are collected, a large biobank is established that
provides extensive opportunities for future research.
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